Atezolizumab, an anti-programmed death-ligand 1 monoclonal antibody, and bevacizumab, an anti-VEGF monoclonal antibody, were approved in over 85 countries for the treatment of patients with unresectable HCC [51], supporting the rationale for their combination with TACE to observe their synergistic effect. This evidence concerns the gene VEGFA and hepatocellular carcinoma.